IFNA2 and Autoimmunity: This is based on an association reported between the development of autoimmunity and favorable antitumor effects for several forms of immunotherapy including IFN-α2b, Interleukin (IL)-2 and anti-CTLA4 blocking antibodies among patients with melanoma [9–20].